Danaher Corporation Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Danaher Corporation (DHR).

If you purchased or held Danaher securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Danaher

Danaher Corporation is a Delaware-incorporated global science and technology company with principal executive offices in Washington, D.C. The company operates through three main business segments: Biotechnology, Life Sciences, and Diagnostics.

Danaher’s operations are subject to extensive regulation, including FDA and global medical device standards across product development, manufacturing, and compliance.

What's Being Investigated

The current investigation centers on allegations raised in a securities fraud class action involving Danaher. According to public filings, the class action may be moving past the motion-to-dismiss (MTD) stage. If so, this may further support that company has been or will be materially harmed by the board's alleged misconduct.

The focus of the investigation includes whether Danaher’s officers and directors made misleading statements or omissions about bioprocessing demand normalization, inventory destocking, and related financial guidance.

Key Timeline

• January 27, 2022: 4Q 2021 earnings call. Management said COVID vaccine/therapeutic revenues would be roughly flat at $2B and framed bioprocessing as a high-single to low-double digit grower.
• March 8, 2022: Cowen Healthcare Conference. Danaher emphasized base business high-single digit growth with bioprocessing in high-single/low-double digits and reiterated confidence in $2B COVID-related bioprocessing revenue.
• April 21, 2022: 1Q 2022 earnings call. Executives reaffirmed strong non-COVID bioprocessing growth and guided bioprocessing to high-single/low-double digit growth.
• May 11, 2022: BofA Healthcare Conference. Company cut expected 2022 COVID vaccine/therapeutic revenue by $500 to $600M but said non-COVID bioprocessing mid-teens growth would offset, keeping full-year bioprocessing at high-single/low-double digits.
• July 21, 2022: 2Q 2022 earnings call. Management lowered 2022 COVID revenue to $1B yet maintained bioprocessing outlook at high-single/low-double digits, citing strength across modalities.
• September 15, 2022: Analyst & Investor Day. Company highlighted new Biotechnology segment and reiterated $500M COVID revenue for 2023 with continued strong non-COVID growth in bioprocessing.
• October 20, 2022: 3Q 2022 earnings call. Guidance cut again: 2022 COVID revenue to $800M and bioprocessing to high-single digit growth; inventory and order-trend concerns were still allegedly downplayed.
• November 30, 2022: Evercore HealthCONx Conference. Management allegedly continued to message 2023 bioprocessing strength, keeping $500M COVID revenue assumption and high-single to mid-double digit base growth talk.
• January 24, 2023: 4Q 2022 earnings call. “Base business” definition was revised to exclude all COVID-related sales.
• April 25, 2023: Danaher issues first quarter 2023 earnings release, projecting mid-single-digit base business growth. Investors allege this set market expectations about the company’s performance.
• July 25, 2023: Second quarter 2023 results are released, with management citing “softer” bioprocessing demand and base business declines. The complaint contends this marked a shift from earlier guidance.
• October 24, 2023: Third quarter 2023 results further acknowledge ongoing demand challenges. Investors argue these disclosures raise questions about the accuracy of prior statements.
• August 4, 2025: The court in Hawkins v. Danaher issues an order granting in part and denying in part Danaher’s motion to dismiss the securities class action, allowing certain claims to proceed.

Why Investors May Be Concerned

Investors allege that Danaher may have made misleading statements or omitted material information regarding bioprocessing demand trends and inventory levels. The complaint contends that management’s public guidance projected ongoing growth, while internal data may have reflected a different outlook.

Some stockholders further argue that the board may have lacked effective systems to monitor these mission-critical risks or failed to respond to red flags, raising potential oversight and internal-controls questions.

Additionally, investors point to related-party transactions involving board leadership and executive officers, suggesting possible conflicts of interest or independence concerns.

Your Rights and Next Steps

This is an active investigation into potential breaches of fiduciary duty and securities law violations at Danaher Corporation. Investors who suffered financial losses due to the alleged misrepresentations and omissions can potentially seek to recover those losses through legal action.

Potential Next Steps:

• Join or monitor ongoing derivative litigation that seeks to recover damages or obtain governance reforms on behalf of Danaher
• Stay informed about the progress of the securities class action and any potential settlements

In a derivative action, stockholders act on behalf of the company to address alleged harm caused by officers or directors. If you are considering joining the investigation or want to understand your rights, it is important to act promptly, as certain legal deadlines may apply.

You May Be Entitled to Compensation

Securities investigations and derivative actions are time-sensitive. If you purchased or held Danaher securities and experienced losses during the periods in question, you may be eligible to participate in potential recoveries or governance reforms.

Please complete the form below to join the investigation.